Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 4 | -$1.05 | -$0.48 | -$0.77 |
Q2 2025 | 2 | -$0.70 | -$0.67 | -$0.68 |
Q3 2025 | 2 | -$0.58 | -$0.56 | -$0.57 |
Q4 2025 | 2 | -$0.39 | -$0.38 | -$0.39 |
Q1 2026 | 1 | -$0.33 | -$0.32 | -$0.32 |
Q2 2026 | 1 | -$0.14 | -$0.13 | -$0.13 |
Q3 2026 | 1 | $0.04 | $0.04 | $0.04 |
Q4 2026 | 1 | $0.20 | $0.21 | $0.20 |
SpringWorks Therapeutics, Inc. last posted its earnings results on Thursday, February 20th, 2025. The company reported $-1.04 earnings per share for the quarter, missing analysts' consensus estimates of $-0.72 by $0.32. The company had revenue of 61.55 M for the quarter and had revenue of 191.59 M for the year. SpringWorks Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-3.48 diluted earnings per share) and currently has a price-to-earnings ratio of -13.62. SpringWorks Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 30th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
02/20/2025 | Q4 2024 | -$0.72 | -$1.04 | -0.32 | $57.16 M | $61.55 M |
11/12/2024 | Q3 2024 | -$0.76 | -$0.72 | 0.04 | $53.28 M | $49.30 M |
08/07/2024 | Q2 2024 | -$1.12 | -$0.54 | 0.58 | $34.42 M | $59.73 M |
05/02/2024 | Q1 2024 | -$1.17 | -$1.18 | -0.01 | N/A | $21.01 M |
02/27/2024 | Q4 2023 | -$1.25 | -$1.28 | -0.03 | $860,188 | $5.45 M |
11/02/2023 | Q3 2023 | -$1.31 | -$1.27 | 0.04 | N/A | $5.59 M |
08/02/2023 | Q2 2023 | -$1.25 | -$1.25 | 0 | N/A | $5.83 M |
05/03/2023 | Q1 2023 | -$1.25 | -$1.11 | 0.14 | N/A | $5.56 M |
02/28/2023 | Q4 2022 | -$1.21 | -$1.12 | 0.09 | N/A | $5.80 M |
11/03/2022 | Q3 2022 | -$1.31 | -$1.35 | -0.04 | N/A | $838,000 |
08/04/2022 | Q2 2022 | -$1.26 | -$1.41 | -0.15 | N/A | $348,000 |
05/05/2022 | Q1 2022 | -$1.07 | -$1.26 | -0.19 | N/A | $5,000 |
02/24/2022 | Q4 2021 | -$0.87 | -$1.15 | -0.28 | N/A | $0 |
11/04/2021 | Q3 2021 | -$0.77 | -$0.84 | -0.07 | N/A | $121,000 |
08/04/2021 | Q2 2021 | -$0.70 | -$0.97 | -0.27 | N/A | $170,000 |
05/05/2021 | Q1 2021 | N/A | -$0.62 | N/A | N/A | $230,000 |
02/25/2021 | Q4 2020 | -$0.10 | $0.30 | 0.4 | N/A | $35.00 M |
11/12/2020 | Q3 2020 | -$0.49 | -$0.51 | -0.02 | N/A | $0 |
08/12/2020 | Q2 2020 | -$0.31 | -$0.47 | -0.16 | N/A | $0 |
05/12/2020 | Q1 2020 | -$0.40 | -$0.37 | 0.03 | N/A | $0 |
SpringWorks Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 30th, 2025 based offlast year's report dates.
The conference call for SpringWorks Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for SpringWorks Therapeutics, Inc.'s latest earnings report can be read online.
SpringWorks Therapeutics, Inc. (:SWTX) has a recorded annual revenue of $191.59 M.
SpringWorks Therapeutics, Inc. (:SWTX) has a recorded net income of $-258,131,000.SpringWorks Therapeutics, Inc. has generated $-3.48 earnings per share over the last four quarters.
SpringWorks Therapeutics, Inc. (:SWTX) has a price-to-earnings ratio of -13.62 and price/earnings-to-growth ratio is -2.11.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED